# SHR-A2102

Source: https://onco.cc/drugs/shr-a2102/  
OnCo record `shr-a2102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SHR-A2102 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for cervical cancer, non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.

## Summary

SHR-A2102 is an investigational agent whose form is not stated in the registry developed by Shanghai Hengrui Pharmaceutical and Suzhou Suncadia Biopharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SHR-A2102: injection, 80mg/ bottle, intravenous drip. It is the investigational product in 9 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07418749 (A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer), in cervical cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma and bladder & urothelial cancer. The largest, NCT06895928, plans to enrol 400 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Notes

- 23 Sept 2026: target and payload are not on any record OnCo reads (no paper is linked here and the registry states neither), so the open drug engine lists SHR-A2102 as not placed rather than guessing; add the target and payload with a source to put it in the grid.

## Sources

- ClinicalTrials.gov: trials of SHR-A2102: https://clinicaltrials.gov/search?intr=SHR-A2102

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- trials: [A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour](https://onco.cc/trials/nct06915142/), [A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06589778/), [A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct07229729/), [A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer](https://onco.cc/trials/nct07418749/), [A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy](https://onco.cc/trials/nct06654440/), [A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct07393542/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer](https://onco.cc/trials/nct07059221/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer](https://onco.cc/trials/nct06474468/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06512051/), [A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma](https://onco.cc/trials/nct06639347/), [A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct06417554/), [A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors](https://onco.cc/trials/nct06895928/), [Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)](https://onco.cc/trials/nct06879145/), [Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects](https://onco.cc/trials/nct07175220/), [Reverse Triple Negative Immune Resistant Breast Cancer](https://onco.cc/trials/nct05076682/), [SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer](https://onco.cc/trials/nct06819319/)

---
JSON: https://onco.cc/api/v1/entities/shr-a2102.json